EU Pharmaceutical Pricing and Reimbursement and Overview of UK National Institute for Health and Care Excellence (NICE) Processes

Commissioners, regulators, and payers are making increasing evidential demands to show value in relation to the pricing and reimbursement of innovative medicines. Although the mechanisms differ, these demands stem from the same driver—the perceived need to control healthcare product budgets. Join our London lawyer Paul Ranson for a one-hour webinar to discuss the issues and challenges arising from the growing need for producers to demonstrate value and share risk.

Topics will include:

• EU-level controls and the consequences of member state autonomy
• Pricing strategies for specialty products and rare diseases in the EU 
• Health technology assessment and outcomes research for demonstrating and promoting value
• Risk-sharing agreements, patient access schemes, and controls on drug spend
• An overview of UK NICE processes and criteria